Biobeat’s remote patient monitoring health-AI platform includes a wearable monitor which utilizes a photoplethysmography-based (PPG) sensor to continuously provide accurate patient readings of 13 health parameters, including cuffless blood pressure, pulse rate, respiratory rate, blood oxygen saturation, and more. Aggregated patient health data is viewed by medical staff via Biobeat’s secure cloud-based patient management platform, which utilizes a real-time early warning score system that incorporates advanced AI-based algorithms to provide alerts on patient health status and potential deterioration. Biobeat’s wearable devices are the first devices to be FDA-Cleared for cuffless non-invasive blood pressure monitoring and are also CE Mark certified.

Conversa offers an industry leading Automated Virtual Care and Triage™ platform that enables health systems to remotely monitor, analyze and communicate with patients and healthcare consumers at scale—for chronic care, post acute, perioperative, oncology, OBGYN, prevention and wellness, and many other use cases. The platform automates care where possible, identifies at-risk patients and provides digital triage to higher levels of care for those patients when necessary, e.g., phone calls, telehealth, e-visits or scheduling in-person consults.

Conversa is healthcare’s leader in delivering personalized, automated engagement at scale for patients, members, employees, and consumers. With Conversa Connect™, its proprietary patient profiling and health signals engine, and an extensive library of clinically-intelligent engagement programs, Conversa enables healthcare organizations to effectively and efficiently manage patients across the care continuum. Leading health systems, payers, and pharma companies are using Conversa to develop meaningful relationships and drive better health outcomes at scale. To learn more, visit conversahealth.com, follow @ConversaHealth or text HELLO to 77877.

Differing from traditional methods in that it is cuffless, Biobeat’s wireless, non-invasive, medical-grade chest-worn device enables blood pressure monitoring by automatically capturing critical patient health data throughout the day. Easy and intuitive to use and apply, it is designed to be set up at patients' homes or at the clinic, without the need for the presence of medical personnel. Since the patient is unaware of the measurements being taken with our optical sensor, this eliminates the "white coat" effect seen with cuff-based devices.

The Biobeat device is providing not only the blood pressure values, but also the Pulse Rate, Mean Arterial Pressure, Cardiac Output, and Systemic Vascular Resistance. This information will help the practitioner with clinical insights of the root cause of hypertension, as well as helping to better adjust medications, thus improving outcomes.

CB Insights, technology market intelligence company, issued a new report ranking Conversa Health tops (among 200 companies reviewed) in the “leader” category of its analysis of companies providing artificial intelligence-enabled chatbots for self-triage. Conversa scored highest in CB Insights’ analysis on both “ability to execute” and “market strength.” https://conversahealth.com/automated-self-triage/.

With Conversa Connect™, its proprietary patient profiling and health signals engine, and its extensive library of Virtual Care programs, Conversa enables healthcare organizations to serve automated, personalized doctor-patient conversation experiences around chronic condition management, post-hospital discharge, pre- and post-surgery, medication adherence, consumer health education and lifestyle health coaching.

More impactful results than others

• Improved patient satisfaction: 97% of patients feel Amwell-Conversa helps them manage their care
• Better patient engagement: 87% of patient feel more connected with following their care plan
• Reducing procedure show rates: Over 70% reduction in colonoscopy no shows
• Care team satisfaction: 82% of care team members recommend using Amwell-Conversa with their patients
• Reducing hospital readmission: ~32%+ reduction in readmission rates among Medicare patients
• Improved treatment adherence: 89% reduction in premature treatment among cancer patients

And more third party validation than other competing companies https://conversahealth.com/best-remote-diagnostics-company/